We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
The length of CEF (Cytomegalovirus, Epstein-Barr Virus, Influenza Virus) control peptide is 8 to 12 amino acids, and its sequence is derived from human cytomegalovirus, EB virus and influenza virus 1. These peptides are used to stimulate CD8+T cells to release IFN- γ. In the detection of many kinds of cytokines such as ELISPOT, they have important application value as positive control peptides. CEF peptides were first screened in 2002 based on their ability to recognize CD8+T cells. It comes from the antigenic epitope of the virus, so it has the antigenic property.
CEF peptide is composed of 8 to 11 amino acids, and the sequence is as follows: GILGFVFTL (influenza A, HLA-A2), FMYSDFHFI (influenza A, HLA-A2), CLGGLLTMV (EBV, HLA-A2), GLCTLVAML (EBV, HLA-A2), NLVPMVATV (HCMV, HLA-A2).
CEF peptide can stimulate CD8+T cells to produce specific interferon-γ, which can be used as a positive control for the detection of γ-ELISA and F-Spot in human peripheral blood mononuclear cells (PBMCs). CEF control peptides are used as positive controls in ELISPOT tests to study specific immune responses to a variety of diseases, including infection, cancer, allergies and autoimmune diseases. In this case, the CEF peptide ensures that the cells in the study are active and visible. ELISPOT is also useful in developing vaccines, especially in HIV vaccines, where CEF peptides are also used as control.
References
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com